As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner. Here, we introduce our IVD antibody development services targeting CD10 marker.
CD10
CD10, also known as acute primary lymphocytic leukemia cell common antigen, is a neutral endopeptidase associated with the cell membrane. The enzyme uses zinc ion as a prosthetic group and can be inhibited by EDTA, phosphoramide, therefore it is a metal enzyme. The peptide bond formed by hydrolysis of the α-amino group of the hydrophobic amino acid produces a polypeptide having phenylalanine, proline or tyrosine as the first residue. It is expressed in a wide range of normal cells and has been shown to be a cell surface marker of tissue stem cells in the bone marrow.
Fig.1 Role of CD10 in inactivating multiple physiologically active peptides.1
CD10 as Marker of Sepsis
Acute lymphoblastic leukemia (ALL) is a common malignant hematological malignancy in adults and can cause severe sepsis when infected. There is a high degree of heterogeneity in biology. CD10 is a neutral peptidase greater than 45 kb located on the 3q25.2 band of chromosome 3 and has a selective cleavage at the 5' end and can produce 4 different mRNA transcripts. The CD10 antigen is expressed on precursor B cells and transiently appears at various stages of B cell maturation and differentiation, but is not presented on the surface of hematopoietic stem cells and mature B cells. It may play an important role in the maturation, differentiation and mutation of B cells. The expression of CD10 in diffuse large B-cell lymphoma (DLBCL) can improve its survival. Some studies have also found that the expression of CD10 can promote the apoptosis of DLBCL tumor cells and has a significant correlation with the clinical stage. In addition to DLBCL, CD10 expression also differs in the clinical features of follicular lymphoma (FL). The CD10 expression is still being used to evaluate children with ALL with minimal residual disease (MRD). The more CD10-negative cells, the higher the MRD test, and the worse the prognosis, the higher the intensity of chemotherapy needs to be.
Fig.2 CD10 as a Marker of Cells with Tumor-Initiating Potential.2
IVD Antibody Development Services for CD10 Marker
The more CD10-negative cells in children with minimal residual disease (MRD), the higher the MRD test, the worse the prognosis and the higher the intensity of chemotherapy. Negative CD10 can be used as a risk factor for prognosis of ALL in adults and provide a reference for CD10 targeted therapy. Creative Biolabs offers high-quality anti-CD10 antibody development services to global clients. Besides antibody generation, Creative Biolabs also offers diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.
Creative Biolabs has successfully completed numerous IVD antibody generation and development projects for clients across the globe. If you are interested in our IVD antibody discovery services, please contact us for more details.
References
For Research Use Only.
